Pfizer launches Sayana Press long-acting reversible contraceptive which can be administered at home instead of a GP surgery or clinic

This article is more than 5 years old

This article is more than 5 years old

The UK’s first self-injectable contraceptive for women is available for use at home, Pfizer has said.



The Sayana Press long-acting reversible contraceptive has received a licence, which means women can inject themselves at home instead of having to go to their GP surgery or clinic.

Contraceptive injection raises risk of HIV, research warns Read more

The Medicines and Healthcare Products Regulatory Agency (MHRA) has extended the label for the product. Each jab provides contraception for at least 13 weeks.

Women will need to see a healthcare professional for training but then can administer Sayana at home, although they will still be called for yearly check-ups.

Seema Patel, a medical director at Pfizer, said: “When it comes to contraception, women may require different options that suit them at different times in their lives.

“We appreciate that many women are very busy and that visiting their healthcare professional regularly to pick up their contraception can be a challenge.

“With around 5 million women in the UK choosing a hormonal contraceptive, self-injectable Sayana Press could offer an alternative to women who are short on time yet still want to take control of their family planning.”